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Leishmaniasis is a significant worldwide health problem for which no vaccine exists. Acti-
vation of CD4+ and CD8+ T cells is crucial for the generation of protective immunity
against parasite. Recent trend in vaccine design has been shifted to epitope-based vac-
cines that are more specific, safe, and easy to produce. In the present study, four known
antigenic Leishmania infantum proteins, cysteine peptidase A (CPA), histone H1, KMP-11,
and Leishmania eukaryotic initiation factor (LeIF) were analyzed for the prediction of bind-
ing epitopes to H2d MHC class I and II molecules, using online available algorithms. Based
on in silico analysis, eight peptides including highly scored MHC class I- and II-restricted
epitopes were synthesized. Peptide immunogenicity was validated in MHC compatible
BALB/c mice immunized with each synthetic peptide emulsified in complete Freund’s adju-
vant/incomplete Freund’s adjuvant. CPA_p2, CPA_p3, H1_p1, and LeIF_p6 induced strong
spleen cell proliferation upon in vitro peptide re-stimulation. In addition, the majority of
the peptides, except of LeIF_p1 and KMP-11_p1, induced IFN-γ secretion, while KMP-
11_p1 indicated a suppressive effect on IL-10 production. CPA_p2, CPA_p3, LeIF_p3, and
LeIF_p6 induced IFN-γ-producing CD4+ T cells indicating a TH1-type response. In addition,
CPA_p2, CPA_p3, and H1_p1 induced also the induction of CD8+ T cells. The induction of
peptide-specific IgG in immunized mice designated also the existence of B cell epitopes
in peptide sequences. Combining immunoinformatic tools and experimental validation, we
demonstrated that CPA_p2, CPA_p3, H1_p1, H1_p3, CPA_p2, LeIF_p3, and LeIF_p6 are
likely to include potential epitopes for the induction of protective cytotoxic and/orTH1-type
immune responses supporting the feasibility of peptide-based vaccine development for
leishmaniasis.
Keywords: in silico analysis, cysteine peptidase A, histone H1, kinetoplastid membrane protein 11, Leishmania
eukaryotic initiation factor, lymphocyte proliferation, CD8+IFN-γ+ T cells, CD4+IFN-γ+ T cells
INTRODUCTION
Leishmaniasis, a vector-borne parasitic disease, is caused by dimor-
phic protozoan flagellates of the genus Leishmania with a world-
wide distribution. The disease is characterized by diversity and
complexity, presenting a wide spectrum of clinical forms in
humans ranging from self-healing cutaneous leishmaniasis (CL)
to fatal visceral leishmaniasis (VL). In VL, parasites colonize inter-
nal organs, primarily the spleen, liver, and bone marrow. With an
estimated 0.5 million cases per year, VL has emerged as an impor-
tant public-health concern with major clinical and socioeconomic
impacts1. In South Europe, VL is caused almost exclusively by
Leishmania (L.) infantum, which is transmitted as a zoonosis with
the domestic dog serving as the main reservoir of the parasite (1).
Current attempts against leishmaniasis are based on chemotherapy
to alleviate disease (2, 3) and on vector control to reduce trans-
mission (4). Toxic side effects and growing resistance to available
therapeutic drugs against VL has made the global demand for an
1http://www.who.int/en/
effective vaccine capable to elicit a protective immune response, a
major public-health priority.
Despite the substantial knowledge regarding the various life
stages of the parasite, the considerable inter-specific diversity, the
extraordinary host evasive mechanisms of parasite and the hetero-
geneity of population (5, 6), effective vaccine development against
human VL represents an unprecedented challenge. Although a
great number of potent vaccine candidates has shown promis-
ing results in mice (7, 8) and dogs (9–11), none of them has
entered human trials except for LeishF1 with reported phase I
and II clinical trials (12, 13).
Antigen identification is considered as a significant barrier
in vaccine design, as this is usually achieved through time con-
suming and labor-intensive in vitro and in vivo experiments.
Efforts have thus focused on developing novel strategies for more
rational and faster antigen identification among large numbers
of pathogen proteins. Furthermore, recent reports support that
epitope-based vaccines appear to be capable of inducing more
potent responses than whole protein vaccines (14). Until recently,
the search of immunodominant peptides relied on the direct
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testing of overlapping peptides or peptide libraries. T cell epitope
prediction by bioinformatic analysis of protein sequences has been
proposed as a promising strategy for vaccine development and an
increasing number of tools have been developed, based on differ-
ent algorithms and methods (15, 16). There is great possibility of
missing the emergence of the sequence mutants that would poten-
tially escape the vaccine’s protective effect. Moreover, the fact that
T cells from genetically distinct populations would recognize and
respond to a single peptide epitope, underline the need of iden-
tifying one or more epitope(s) that bind to multiple HLA alleles
and cover close to 100% of the genetically diverse human popula-
tion (17). Multi-peptide-based vaccines are designed to generate
a diverse immune response to incorporate antigens and to reduce
limitations due to MHC restriction into a single entity.
The effectiveness of a vaccine depends on its capacity to ensure
long-lasting cell-mediated immunity. In VL, there is evidence that
an interplay of T helper cytokines (TH1/TH2) is observed, while
resistance or resolution of infection is associated with dominant
TH1 response and CD8+ T cells (18–20). Furthermore, successful
treatment of VL with sodium stibogluconate requires the presence
of both CD4+ and CD8+ T cells (21) accompanied with IL-12 and
IFN-γ production (22). In contrast, TH2 response with IL-4 and
IL-10 production results in susceptibility to infection and develop-
ment of severe disease. Murine models of leishmaniasis have been
extensively used to study the pathogenesis of the disease and to
test novel therapeutic agents or potent vaccine candidates in pre-
clinical studies. One of the most widely studied and commonly
used model of VL is the BALB/c strain of mice infected intra-
venously with L. infantum. Although this strain is considered to
be susceptible and the infection progresses during the first month,
the infection is then controlled by the host immune response. This
mouse model is comparable to self-controlled oligosymptomatic
cases and therefore is useful for the study of the protective immune
response (23).
Several reports demonstrate that different leishmanial antigens
elicit desired TH1 and CTL responses capable to sustain protec-
tion against experimental challenges (24). Among these antigens,
cysteine peptidase A (CPA), histone H1, kinetoplastid membrane
protein 11 (KMP-11), and Leishmania eukaryotic initiation fac-
tor (LeIF) are considered important immunogens, as supported
by numerous studies. Specifically, CPA induces protection against
L. major in the experimental model of CL through development
of specific TH1 immune responses (25–27). Histone H1 and KMP-
11, structural highly conserved proteins, are able to trigger specific
immune responses (28–33), and immunization with these pro-
teins confer protection against L. major or L. infantum infections
in experimental animal models (34–38). Moreover, LeIF, originally
described as a TH1-type natural adjuvant, is capable of stimulating
IL-12 mediated TH1 responses in PBMCs of patients (39). Fur-
thermore, recombinant forms of CPA, histone H1, and KMP-11
act as potent B cell immunogens since they are recognized by sera
from either recovered or active cases of CL and VL, as well as by
sera from asymptomatic or symptomatic dogs with leishmaniasis
(40–45).
In the present study, we applied immunoinformatics using
currently available online algorithms in order to identify poten-
tially immunogenic T cell epitopes from the above mentioned
L. infantum proteins, and design multi-epitope peptides contain-
ing both MHC class I and II-restricted epitopes as possible can-
didate peptide vaccines for VL. Immunogenicity of the synthetic
multi-epitope peptides in terms of T cell activation was validated
in immunized BALB/c mice by analyzing peptide-specific prolif-
erative responses and cytokine production by CD8+ and CD4+ T
cells.
MATERIALS AND METHODS
PROTEIN SEQUENCE RETRIEVAL AND PREDICTION OF MHC CLASS I
AND II BINDING EPITOPES
Full protein sequences of selected proteins, CPA, Histone H1,
KMP-11, and LeIF, were retrieved from GenBank data2 on
JPCM5 strain (MCAN/ES/98/LLm-887) and analyzed by Sig-
nalP3 for the prediction of signal peptides and transmembrane
domains (Table 1). Potential MHC class I and II binding epitopes
derived from the four L. infantum proteins, were predicted by
in silico analysis, using three online available, binding algorithms
named SYFPEITHI4, BIMAS5, and NetMHCII6. The cut-off score
was adjusted to ≥18 for SYFPEITHI, ≥100 for BIMAS, and a
default prediction threshold (binding affinity<500 nM) depicting
accuracy >85% was used for NetMHCII (Tables 2 and 3).
SYNTHETIC MULTI-EPITOPE PEPTIDES
Based on the prediction results of the algorithms used, 9-mer
epitopes MHC class I-restricted and 15-mer epitopes MHC class
II-restricted giving high score against H2d alleles were extracted
and combined in order to generate multi-epitope peptides for
each L. infantum protein. Thus, 8 peptides, 20–30 amino acid
(aa) length, were designed in a way that each peptide included
at least one MHC class I-restricted epitope scored very high, as
well as adjacent or overlapping MHC class II-restricted epitopes
scored also high. Sequence homology between each multi-epitope
peptide and mouse proteome were analyzed on BLAST database7
and peptides with 100% identity were excluded or re-designed to
2http://www.ncbi.nlm.nih.gov/genbank
3http://www.cbs.dtu.dk/services/SignalP
4http://www.syfpeithi.de
5http://www-bimas.cit.nih.gov/molbio/hla_bind
6http://www.cbs.dtu.dk/services/NetMHCII
7blast.ncbi.nlm.nih.gov/Blast.cgi
Table 1 | L. infantum proteins selected as candidate antigens for
epitope mapping.
Protein
abbreviation
Protein name Protein
length (aa)/
mass (kDa)
GenBank
accession
number
CPA Cysteine peptidase A 354/39.0 CAM67356
Histone H1 Histone H1 111/11.1 ABN54817
KMP-11 Kinetoplastid
membrane protein 11
92/11.2 CAA64883
LeIF Leishmania eukaryotic
initiation factor
403/45.3 CAM65231
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Table 2 | In silico predicted MHC class I-restricted 9-mer epitopes of L. infantum proteins.
Protein No. of epitope Epitope sequence Scorea
SYFPEITHI BIMAS
H2-Kd H2-Ld H2-Kd H2-Ld H2-Dd
CPA 1 8-FFAIVVTIL-18 23 – 1152 – –
2 84-HYDVSGKFA-92 23 – – – –
3 273-LYFGGVVTL-281 23 – 2400 – –
4 254-AYVGKNGPV-262 22 – 1200 – –
5 23-SALIAQTPL-31 20 – – – –
6 102-LYLNPNYYA-110 20 – 120 – –
7 334-NYVVTATID-343 20 – – – –
8 7-FFFAIVVTI-15 – – 1152 – –
9 165-QWALKNHSL-173 – – 240 – –
10 62-RFNAFKQNM-70 – – 144 – –
11 319-GYIRLAMGS-327 – – 120 – –
12 179-QVLVSCDNI-187 – – 115.20 – –
13 68-QNMQTAYFL-76 – – 115.20 – –
14 160-GNIEGQWAL-168 – – 115.20 – –
Histone H1 15 46-KKAGAKKAV-54 18 – – – –
16 2-SSDSAVAAL-10 17 19 – – –
KMP-11 17 4-TYEEFSAKL-12 20 – 2400 – –
18 47-HYEKFERMI-55 19 – 2000 – –
19 72-HFKQFAEL-79 18 – 960 – –
20 69-HSEHFKQKF-77 – 18 – – –
21 7-EFSAKLDRL-15 – – 960 – –
LeIF 22 385-HYHTQIDEL-393 24 – 2000 – –
23 360-RYGRKGVAI-368 23 – 2000 – –
24 8-APQDQDSFL-16 – 22 – 225 –
25 25-IPSFDDMPL-33 – 22 – 150 –
26 199-LPKDIQVAL-207 – 22 – –
27 344-LPTNKENYL-352 – 22 – 150 –
28 393-LPVDFAAYL-401 – 22 – 150 –
29 14-SFLDDQPGV-22 21 – 576 – –
30 197-RFLPKDIQV-205 21 – 480 – –
31 100-LSPTRELAL-108 – 21 – –
32 187-GFADQIYEI-195 20 – 960 – –
33 318-SRVLVTTDL-326 20 – – – –
34 23-RPIPSFDDM-31 – 20 – 150 –
35 123-NSSKFCETF-131 – 20 – – –
36 265-VSIAQSVIF-273 – 20 – – –
37 222-KFMRDPVRI-230 – – 2304 – –
38 195-IFRFLPKDI-203 – – 960 – –
39 272-IFANTRRKV-280 – – 288 – –
40 312-TFRSGSSRV-320 – – 288 – –
41 164-RGALRTESL-172 – – – – 120
aThe cut-off score was adjusted to ≥18 for SYFPEITHI, ≥100 for BIMAS, and <500 for NetMHCII.
avoid potential autoimmunity (Table 4). Two multi-epitope pep-
tides of CPA (160–189 and 273–302 aa) and Histone H1 (1–20
and 43–61 aa), one peptide of KMP-11 (4–23 aa), and three pep-
tides of LeIF (6–35, 181–210, and 371–400 aa) were synthesized by
GeneCust (Labbx, Dudelange, Luxembourg) with purity ≥95%.
Synthetic peptides were dissolved in DMSO, acetic acid (10% in
dH2O), or dH2O according to their hydrophobicity, by vigorous
pipetting and stored in aliquots, in−80°C until use. Peptides solu-
tions were found endotoxin free, since LPS concentration was
<5 EU/mg as determined by LAL Test Cartridges Portable Test
www.frontiersin.org June 2014 | Volume 5 | Article 268 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agallou et al. Validation of multi-epitope L. infantum peptides
Table 3 | In silico predicted MHC class II-restricted 15-mer epitopes of L. infantum proteins.
Protein No. of epitope Epitope sequence Scorea
SYFPEITHI NetMHCII
H2-IAd H2-IEd H2-IAd
CPA 1 149-MCGSCWAFATTGNIE-163 28 – –
2 246-PHDEEEIAAYVGKNG-260 27 – –
3 114-KDYKEHVHVDDSVRS-128 26 – –
4 257-GKNGPVAVAVDATTW-271 26 – –
5 32-GVDDFIASAHYGRFK-46 25 – –
6 312-GSSWGEKGYIRLAMG-326 – 24 –
7 4-RNPFFFAIVVTILFV-18 23 – –
8 5-NPFFFAIVVTILFVV-19 23 – –
9 13-VTILFVVCYGSALIA-27 22 – –
10 172-SLVSLSEQVLVSCDN-186 22 – –
11 174-VSLSEQVLVSCDNID-188 22 – –
12 12-VVTILFVVCYGSALI-26 21 – –
13 260-GPVAVAVDATTWQLY-274 21 – –
14 279-VTLCFGLSLNHGVLV-293 21 – –
15 67-KQNMQTAYFLNAHNP-81 20 – –
16 273-LYFGGVVTLCFGLSL-287 20 – –
17 301-KPPYWIVKNSWGSSW-315 20 – –
18 328-NQCLLKNYVVTATID-342 20 – –
19 216-SYPYTSAGGTRPPCH-230 – 20 –
20 308-KNSWGSSWGEKGYIR-322 – 20 –
Histone H1 21 1-MSSDSAVAALSAAMT-15 31 – 88.3
22 27-KTAAKKAAAKKAAAK-41 29 – 182.6
23 32-KAAAKKAAAKKAGAK-46 29 – 239.9
24 37-KAAAKKAGAKKAGAK-51 29 – –
25 42-KAGAKKAGAKKAVRK-56 29 – –
26 2-SSDSAVAALSAAMTS-16 28 – 123.7
27 56-KVATPKKPAKKAAKK-70 24 – –
28 36-KKAAAKKAGAKKAGA-50 – 24 –
29 41-KKAGAKKAGAKKAVR-55 – 24 –
30 71-AAKKPAKKVAKKPAK-85 – 24 –
31 16-SPQKSPRSSPKKTAA-30 – 22 –
32 21-PRSSPKKTAAKKAAA-35 – 22 –
33 26-KKTAAKKAAAKKAAA-40 – 22 163.5
34 31-KKAAAKKAAAKKAGA-45 – 22 190.3
35 45-AKKAGAKKAVRKVAT-59 – 22 –
36 51-KKAVRKVATPKKPAK-65 – 22 –
37 55-RKVATPKKPAKKAAK-69 – 22 –
38 59-TPKKPAKKAAKKAAK-73 – 22 –
39 63-PAKKAAKKAAKKPAK-77 – 22 –
40 67-AAKKAAKKPAKKVAK-81 – 22 –
41 75-PAKKVAKKPAKKAAK-89 – 22 –
42 79-VAKKPAKKAAKKPAK-93 – 22 –
43 83-PAKKAAKKPAKKPAK-97 – 22 –
44 87-AAKKPAKKAAKKAAK-101 – 22 –
45 91-PAKKPAKKAAKKAAK-105 – 22 –
(Continued)
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Table 3 | Continued
Protein No. of epitope Epitope sequence Scorea
SYFPEITHI NetMHCII
H2-IAd H2-IEd H2-IAd
46 95-PAKKAAKKAAKKAAA-109 – 22 –
47 5-SAVAALSAAMTSPQK-19 21 – 382.8
48 76-AKKVAKKPAKKAAKK-90 21 20 –
49 96-AKKAAKKAAKKAAAK-110 21 – –
50 29-AAKKAAAKKAAAKKA-43 – – 107.9
51 30-AKKAAAKKAAAKKAG-44 – – 119.1
52 25-PKKTAAKKAAAKKAA-39 – – 119.6
53 24-SPKKTAAKKAAAKKA-38 – – 138.5
54 3-SDSAVAALSAAMTSP-17 – – 166.2
55 28-TAAKKAAAKKAAAKK-42 – – 183.3
56 35-AKKAAAKKAGAKKAG-49 – – 208.6
57 34-AAKKAAAKKAGAKKA-48 – – 232.0
58 4-DSAVAALSAAMTSPQ-18 – – 272.1
59 48-AGAKKAVRKVATPKK-62 – – 295.2
60 33-AAAKKAAAKKAGAKK-47 – – 317.8
61 49-GAKKAVRKVATPKKP-63 – – 457.6
KMP-11 62 4-TYEEFSAKLDRLDEE-18 23 – –
63 75-QKFAELLEQQKAAQN-89 19 – –
64 45-KEHYEKFERMIKEHT-59 – 18 –
65 74-KQKFAELLEQQKAAQ-88 – 18 –
LeIF 66 100-LSPTRELALQTAEVI-114 28 – 264.2
67 320-VLVTTDLVARGICVH-334 28 – –
68 199-LPKDIQVALFSATMP-213 27 – –
69 387-HTQIDELPVDFAAYL-401 27 – –
70 138-QDDLRKLQAGVIVAV-152 26 – 205.3
71 166-ALRTESLRVLVLDEA-180 26 – –
72 169-TESLRVLVLDEADEM-183 26 – –
73 62-RGGDIIAQAQSGTGK-76 25 – –
74 140-DLRKLQAGVIVAVGT-154 24 – 256.8
75 142-RKLQAGVIVAVGTPG-156 24 – –
76 259-MDLYETVSIAQSVIF-273 24 – –
77 223-FMRDPVRILVKRESL-237 – 24 –
78 325-DLVARGIDVHHVNIV-339 23 – –
79 168-RTESLRVLVLDEADE-182 22 – –
80 263-ETVSIAQSVIFANTR-277 22 – –
81 293-TVSSMHAEMPKSDRE-307 22 – –
82 314-RSGSSRVLVTTDLVA-328 22 – –
83 268-AQSVIFANTRRKVDW-282 – 22 –
84 16-LDDQPGVRPIPSFDD-30 20 – –
85 71-QSGTGKTGAFSIGLL-85 20 – –
86 107-ALQTAEVISRIGEFL-121 20 – –
87 174-VLVLDEADEMLSQGF-188 20 – –
88 255-LDTLMDLYETVSIAQ-269 20 – –
89 376-VELLHEIEAHYHTQI-390 20 – –
90 77-TGAFSIGLLQRLDFR-91 – 20 –
(Continued)
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Table 3 | Continued
Protein No. of epitope Epitope sequence Scorea
SYFPEITHI NetMHCII
H2-IAd H2-IEd H2-IAd
91 81-SIGLLQRLDFRHNLI-95 – 20 –
92 158-VSDVIKRGALRTESL-172 – 20 –
93 102-PTRELALQTAEVISR-116 – – 95.3
94 103-TRELALQTAEVISRI-117 – – 95.4
95 101-SPTRELALQTAEVIS-115 – – 163.8
96 139-DDLRKLQAGVIVAVG-153 – – 249.0
97 99-VLSPTRELALQTAEV-113 – – 263.1
98 98-LVLSPTRELALQTAE-112 – – 287.6
99 141-LRKLQAGVIVAVGTP-155 – – 296.7
100 49-PSSIQQRAIAPFTRG-63 – – 320.9
101 48-KPSSIQQRAIAPFTR-62 – – 378.0
102 50-SSIQQRAIAPFTRGG-64 – – 434.6
103 97-GLVLSPTRELALQTA-111 – – 452.0
104 290-SNHTVSSMHAEMPKS-304 – – 489.1
aThe cut-off score was adjusted to ≥18 for SYFPEITHI, ≥100 for BIMAS, and <500 for NetMHCII.
System (Endosafe, Charles River Laboratories, USA). Synthetic
multi-epitope peptides were also checked for the presence of 9-
mer or/and 15-mer epitopes able to bind to HLA alleles (A2, A3,
A24, B7, B15, DP, DQ, DR supertypes) using the above mentioned
algorithms (Table 4). In addition, data on the crystal structure
of HLA-A2 and HLA-DRB1 molecules were obtained from Pro-
tein Data Bank (PDB, codes 1HHG and 2SEB, respectively) and
multi-epitope peptides of length 30 aa were transformed into PDB
files using SWISS-MODEL, and each of them was docked with
HLA-A2 or HLA-DRB1 molecule using the ClusPro program8 for
structure-based analysis (46–49).
IMMUNIZATION OF BALB/C MICE
Eight groups of female BALB/c mice (n= 8/group), 6–8 weeks
old, were immunized subcutaneously at upper and lower dorsal
region, with 100µl emulsion consisting of 50µg of each synthetic
multi-epitope peptide in complete Freund’s adjuvant (CFA). Mice
were also received a second immunization with 100µl emulsion of
50µg of the same peptide in incomplete Freund’s adjuvant (IFA),
as well as a third immunization with 50µg of peptide alone in
PBS at 2 weeks intervals. Two sex and age matched groups of mice
(n= 8/group) immunized similarly either with the adjuvant or
with PBS alone, were served as control groups.
Animals were obtained from the breeding unit of the Hellenic
Pasteur Institute (Athens, Greece) and reared in institutional facil-
ities under specific pathogen-free conditions, receiving a diet of
commercial food pellets and water ad libitum. All experimen-
tal procedures had been approved by the institutional Animal
Bioethics Committee regulating according to the EU Directive
2010/63 and the National Law 2013/56.
8http://cluspro.bu.edu
CULTURE OF LYMPHOCYTES AND PROLIFERATION ASSAYS
Fifteen days post the third immunization, spleens from immunized
and control mice (n= 3/group) were collected in aseptic condi-
tions and used for the preparation of single cell suspensions in
RPMI-1640 medium (Biochrom AG, Berlin, Germany) supple-
mented with 2 mM l-glutamine, 10 mM Hepes, 24 mM NaHCO3,
0.05 mM β-mercaptoethanol, 100 U/ml penicillin, 100µg/ml
streptomycin, and 10% (v/v) heat inactivated fetal bovine serum
(FBS; Gibco, Paisley, UK) at a density of 1× 106 cells/ml. Cell
viability was >95% as determined by trypan blue exclusion. A
volume of 200µl/well were placed in triplicate into 96-well U-
bottomed plates in the presence of various concentrations of each
synthetic multi-epitope peptide ranging from 5 to 40µg/ml and
incubated for 96 h in 5% CO2 at 37°C in a humidified atmos-
phere. The optimal concentration for each peptide was determined
at 10µg/ml and used thereafter for recall stimulation. Cells cul-
tured in medium alone or in the presence of Concanavalin A
(6µg/ml) were served as negative or positive control, respectively.
Cells were pulsed with 1µCi/ml of 3H-TdR (GE Healthcare, Buck-
inghamshire, UK) for the final 18 h of the culture period. Cells
were harvested and 3H-TdR incorporation was determined on a
microplate scintillation counter (Microbeta Trilux, Wallac, Turku,
Finland). The results were expressed as ∆cpm (cpm of cells from
immunized mice stimulated with peptide – cpm of immunized
mice cultured in medium alone). Proliferative response against
to each synthetic peptide giving ∆cpm> 2000 was considered as
positive.
CYTOKINE DETECTION AND FLOW CYTOMETRY
Spleen cells from immunized and control mice (n= 5/group)
were also used for cytokine detection and flow cytometry. Briefly,
1 ml/well of lymphocytes in complete RPMI-1640 medium at a
density of 2× 106 cells/ml were placed in triplicate into 24-well
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Table 4 | Synthetic multi-epitope peptides including MHC class I and II-restricted epitopes.
Peptide name Synthetic multi-epitope peptide sequence Included epitopes HLA supertype
CPA_p2 160-GNIEGQWALKNHSLVSLSEQVLVSCDNIDD-189 165-QWALKNHSL-173 HLA-A2 (A*0201), HLA-A3 (A*03),
HLA-DRB1, HLA-DPA1, HLA-DQA1179-QVLVSCDNI-187
160-GNIEGQWAL-168
172-SLVSLSEQVLVSCDN-186
174-VSLSEQVLVSCDNID-188
CPA_p3 273-LYFGGVVTLCFGLSLNHGVLVVGFNRQAKP-302 273-LYFGGVVTL-281 HLA-A2 (A*0201), HLA-A3 (A*03),
HLA-A24 (A*2402), HLA-DRB1,
HLA-DPA1, HLA-DQA1
279-VTLCFGLSLNHGVLV-293
273-LYFGGVVTLCFGLSL-287
H1_p1 1-MSSDSAVAALSAAMTSPQKS-20 2-SSDSAVAAL-10 HLA-A2 (A*0201), HLA-A3 (A*03),
HLA-DRB1, HLA-DQA11-MSSDSAVAALSAAMT-15
2-SSDSAVAALSAAMTS-16
5-SAVAALSAAMTSPQK-19
H1_p3 43-AGAKKAGAKKAVRKVATPKK-61 46-KKAGAKKAV-54 HLA-A2 (A*0201), HLA-A3 (A*03),
HLA-DRB142-KAGAKKAGAKKAVRK-56
45-AKKAGAKKAVRKVAT-59
KMP-11_p1 4-TYEEFSAKLDRLDEEFNRKM-23 4-TYEEFSAKL-12 HLA-A3 (A*03), HLA-A24, HLA-DRB1,
HLA-DPA1, HLA-DQA17-EFSAKLDRL-15
4-TYEEFSAKLDRLDEE-18
LeIF_p1 6-KIAPQDQDSFLDDQPGVRPIPSFDDMPLHQ-35 8-APQDQDSFL-16 HLA-B7 (B*5101), HLA-B15 (B62),
HLA-DRB1, HLA-DPA1, HLA-DQA125-IPSFDDMPL-33
14-SFLDDQPGV-22
23-RPIPSFDDM-31
16-LDDQPGVRPIPSFDD-30
LeIF_p3 181-DEMLSQGFADQIYEIFRFLPKDIQVALFSA-210 199-LPKDIQVAL-207 HLA-B7 (B*3501, B*5101), HLA-DRB1,
HLA-DPA1, HLA-DQA1197-RFLPKDIQV-205
187-GFADQIYEI-195
195-IFRFLPKDI-203
199-LPKDIQVALFSATMP-213
LeIF_p6 371-VTEKDVELLHEIEAHYHTQIDELPVDFAAY-400 385-HYHTQIDEL-393 HLA-A3 (A*0301), HLA-A24,
HLA-DRB1, HLA-DPA1, HLA-DQA1393-LPVDFAAYL-401
320-VLVTTDLVARGICVH-334
387-HTQIDELPVDFAAYL-401
376-VELLHEIEAHYHTQI-390
plates and stimulated with 10µg/ml of each synthetic multi-
epitope peptide. Cells were cultured for 72 h in 5% CO2 at 37°C
in a humidified atmosphere. At the end of the incubation period,
culture supernatants were collected and stored at−80°C until ana-
lyzed for their cytokine content. The concentrations of IFN-γ and
IL-10 in the supernatants were determined by sandwich ELISA kits
(900-K98, 900-K53; PeproTech, Rocky Hill, NJ, USA) according to
the manufacturer’s instructions. The cytokine concentrations were
calculated by reference to standard curves; detection threshold for
IFN-γ and IL-10 was 23 and 47 pg/ml, respectively.
In parallel, at 48 h of culture period, similarly cultured cells
were exposed for 4 h to 2.5µg/ml brefeldin A (Fluka, Buchs, Ger-
many), washed in FACS buffer (PBS-2% FBS) and stained with
anti-CD4 and anti-CD8 monoclonal antibodies (mAbs) conju-
gated either with FITC (anti-CD4-FITC, clone RM4-5) or PE
(anti-CD4-PE, clone H129.19; anti-CD8-PE, clone 53-6.7) for
30 min. For the identification of intracellular cytokine production,
cells were permeabilized using FACS buffer supplemented with
0.1% (v/v) saponin (Sigma) and stained for 30 min on ice with
anti-IFN-γ conjugated with FITC (clone XMG1.2) or anti-IL-4
conjugated with PE (clone BVD4-1D11) mAbs. In all cases, con-
trol cells were processed similarly using matched isotype control.
All mAbs used in the study, were purchased from BD Biosciences
(Erembodegem, Belgium). For each sample, 20,000 cells were ana-
lyzed on a FACSCalibur (Becton-Dickinson, San Jose, CA, USA)
and the data were processed with Cell Quest Software (Becton-
Dickinson). The percentage of specific cytokine-producing CD4+
or CD8+ T cells relative to total numbers of CD4+ or CD8+ T cells
was determined by analysis of FACS data using the FlowJO soft-
ware package (Tree Star, Inc., Ashland, OR, USA). The percentage
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of peptide-specific cytokine-producing cells was normalized to
their respective proportion in unstimulated cells from mice immu-
nized with CFA/IFA alone, in order to allow for comparison among
all the synthetic multi-epitope peptides.
ENZYME LINKED IMMUNOSORBENT ASSAYS
Blood collected from each group of mice (n= 8/group) at fifteenth
day post the third immunization, were centrifuged at 4000× g
for 5 min and separated sera were aliquoted for the detection of
specific antibodies against each synthetic multi-epitope peptide
by specific ELISAs as previously described (50). In brief, 96-well
microtiter plates were coated with 5µg/ml of each individual pep-
tide in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3), pH
9.6 and left overnight at 4°C. For the detection of total IgG anti-
bodies, 10-fold dilutions of each serum sample in 1% BSA in
PBS-T were added and incubated with HRP-labeled goat anti-
mouse IgG (1/1000 dilution; GE Healthcare, Buckinghamshire,
UK). For the detection of IgG1 and IgG2a isotypes, serum samples
(1/100 dilution) were added and plates were similarly incubated
either with biotin-labeled rat anti-mouse IgG1 (500 ng/ml; AbD
Serotec, Oxford, UK) or IgG2a (250 ng/ml; AbD Serotec) fol-
lowed by the addition of streptavidin–HRP (1/5000 dilution; AbD
Serotec) and incubation for 1 h at 37°C. The cut-off value was
determined as the mean OD value of normal mouse serum in a
1/100 dilution+ 2SD.
STATISTICAL ANALYSIS
Data were expressed as the mean value with the standard devia-
tion (SD) indicated. Statistical significant differences of the mean
values between groups of mice immunized with synthetic multi-
epitope peptide emulsified in CFA/IFA and mice immunized with
CFA/IFA alone were assessed by unpaired Student’s t -test. The
probability (p) of <0.05 was considered to indicate statistical
significance.
RESULTS
IN SILICO PREDICTION OF PROMISING EPITOPES OF L. INFANTUM
PROTEINS BIND TO MHC CLASS I AND II MOLECULES
CPA, Histone H1, KMP-11, and LeIF have already been defined
as candidate antigens. CPA, a protein significantly up-regulated
in mature amastigotes (40), is predicted as a secretory protein by
SignalP (cleavage site between position 24 and 25 residue), while
Histone H1, an also highly expressed protein in mature amastig-
otes (51), KMP-11, a cytoskeleton-associated protein, and LeIF
constitutively expressed in both promastigotes and amastigotes
(45, 52), are predicted as non-secretory. In silico analysis of pro-
teins for the prediction of binding epitopes to H2d MHC class I
and II molecules revealed, in total, 41 9-mer and 104 15-mer pep-
tides, respectively, which scored above the cut-off value of each
algorithm used for the prediction (Tables 2 and 3).
In particular, 14 and 20 highly scored binding peptides to H2-
Kd and H2-IAd/IEd alleles, respectively, were predicted by BIMAS
and SYFPEITHI for CPA. These peptides were spanning through-
out the protein amino-acid sequence and they covered the 69.2%
of its length. In addition, 2 and 41 binding peptides to H2-Kd/Ld
and H2-IAd/IEd alleles, respectively, were predicted by SYFPEITHI
and NetMHCII for Histone H1. The peptides were also spanning
throughout Histone H1 amino-acid sequence, covering the entire
length of the protein. Five and four binding peptides to H2-Kd/Ld
and H2-IAd/IEd alleles, respectively, were predicted by BIMAS and
SYFPEITHI for KMP-11. Peptides were gathered in the middle,
as well as in the amino- and carboxy-terminal region of KMP-
11 sequence, and covered the 55.4% of its length. In regards to
LeIF, 20 and 39 binding peptides to H2-Kd/Ld/Dd and H2-IAd/IEd
alleles, respectively, were predicted by BIMAS, SYFPEITHI, and
NetMHCII. Peptides were spanning throughout LeIF amino-acid
sequence and covered the 79.4% of the entire protein.
SYNTHETIC MULTI-EPITOPE PEPTIDES CONTAINING BOTH MHC CLASS
I- AND II-RESTRICTED EPITOPES
Based on the above data, eight peptides, 20–30 amino-
acid length, were designed and synthesized. At least, one
MHC class I-restricted epitope scored very high, as well
as adjacent or overlapping MHC class II-restricted epitopes
scored also high were nested in each synthetic peptide
(Table 4). These multi-epitope peptides included CPA_p2 (160-
GNIEGQWALKNHSLVSLSEQVLVSCDNIDD-189) and CPA_p3
(273-LYFGGVVTLCFGLSLNHGVLVVGFNRQAKP-302) from
CPA, H1_p1 (1-MSSDSAVAALSAAMTSPQKS-20) and H1_p3
(43-AGAKKAGAKKAVRKVATPKK-61) from Histone H1, KMP-
11_p1 (4-TYEEFSAKLDRLDEEFNRKM-23) from KMP-11,
LeIF_p1 (6-KIAPQDQDSFLDDQPGVRPIPSFDDMPLHQ-35),
LeIF_p3 (181-DEMLSQGFADQIYEIFRFL PKDIQVALFSA-210),
and LeIF_p6 (371-VTEKDVELLHEIEAHYHTQIDELPVDFAAY-
400) from LeIF. Synthetic peptide sequences showed to be retrieved
from highly conserved regions of L. infantum proteins, since pro-
tein BLAST analysis revealed up to 95% residue identity to homol-
ogous sequences of corresponding proteins of strains belonging to
L. major and L. donovani complexes. In addition, promiscuous 9-
mer and 15-mer epitopes bound to HLA alleles (A2, A3, A24, B7,
B15, DP, DQ, DR supertypes) were also nested in synthetic multi-
epitope peptides as predicted by in silico analysis using the above
mentioned algorithms.
VALIDATION OF SYNTHETIC MULTI-EPITOPE PEPTIDES
IMMUNOGENICITY IN MICE
Immunogenicity of the eight synthetic multi-epitope peptides was
validated in BALB/c mice (H2d haplotype) immunized with each
synthetic peptide in combination with CFA/IFA, 15 days post third
immunization. Specific proliferative T cell responses induced by
synthetic multi-epitope peptides were firstly assessed. As shown
in Figure 1A, CPA_p2, CPA_p3, H1_p1, and LeIF_p6 induced
strong proliferation of spleen cells upon in vitro re-stimulation
(∆cpm> 1128± 165) at the optimal dose of 10µg/ml. Of these,
CPA_p2 induced the strongest proliferation, followed by LeIF_p6,
CPA_p3, and H1_p1. The results indicated that four of the
eight candidate peptides could effectively induce spleen cell
proliferation.
To validate the profile of cytokines secreted in response to the
eight synthetic multi-epitope peptides, spleen cell culture super-
natants from immunized mice were analyzed for their content
in IFN-γ and IL-10 at 72 h post respective peptide in vitro re-
stimulation. Quantitation by ELISA revealed that all peptides,
except from LeIF_p1 and KMP-11_p1, induced the secretion of
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FIGURE 1 | Multi-epitope peptide-specific proliferative responses and
cytokine secretion. (A) Proliferative responses. Spleen cells from BALB/c
mice (n=3/group) immunized either with individual peptide emulsified in
CFA/IFA or PBS alone, were re-stimulated in vitro with the respective
peptide (10µg/ml) for 72 h. Cultures were pulsed for the final 18 h with
1µCi of [3H]-TdR and results are depicted as ∆cpm±SD as described in
Section “Materials and Methods.” Spleen cells derived from mice
immunized with PBS alone, stimulated in vitro with ConA (∆cpm:
39743±843) were used for comparison purposes. (B) IFN-γ and (C) IL-10
secretion. Cytokines were detected in culture supernatants of spleen cells
from immunized BALB/c mice (n=5/group), re-stimulated in vitro with the
respective peptide (10µg/ml) for 72 h, by ELISA. The results are expressed
as pg/ml±SD. Significant differences between groups of mice immunized
with each synthetic peptide emulsified in CFA/IFA and the group of mice
immunized with CFA/IFA alone are indicated by * (P<0.05).
high amounts of IFN-γ in comparison to mice immunized with
CFA/IFA alone (Figure 1B). CPA_p3, H1_p1, CPA_p2, and H1_p3
were able to induce the highest secretion of IFN-γ, followed by
LeIF_p3 and LeIF_p6. In contrast, unstimulated spleen cells from
immunized mice produced low levels of IFN-γ spontaneously,
similar to those measured in the culture supernatants of spleen
cells from mice immunized with CFA/IFA alone. The results sug-
gest that the majority of the candidate peptides could induce IFN-γ
secretion.
In addition, low levels of IL-10 were detected in the super-
natants of spleen cells stimulated in vitro with each synthetic
multi-epitope peptide (Figure 1C). These levels were compara-
ble to those detected in the supernatants of unstimulated spleen
cells, as well as in the supernatants of spleen cells from mice immu-
nized with CFA/IFA alone. In particular, KMP-11_p1 indicated a
rather suppressive effect on IL-10 production.
To further confirm the pattern of cytokines induced by each
synthetic multi-epitope peptide, intracellular cytokine production
was determined in spleen cells from immunized mice at 48 h post
peptide in vitro re-stimulation using flow cytometry. As shown
in Figure 2A, none of the peptides tested were able to stimu-
late important peptide-specific IL-4 production by CD4+ T cells,
although a certain predisposition in BALB/c mice has been doc-
umented by previous studies (53). In contrast, CPA_p2, CPA_p3,
H1_p3, LeIF_p3, and LeIF_p6 were able to stimulate important
peptide-specific IFN-γ production by CD4+ T cells, indicating a
TH cell driven toward the TH1 type.
Regarding the ability of the synthetic multi-epitope peptides to
induce the production of IFN-γ by CD8+ T cells, flow cytometry
revealed that one of them, H1_p1 strongly induced the produc-
tion of IFN-γ by splenic CD8+ T cells of immunized mice. H1_p3,
CPA_p2, and CPA_p3 were also able to stimulate peptide-specific
IFN-γ production by CD8+ T cells in a lower level than that
detected in H1_p1 (Figure 2C). Flow cytometry overall results
indicated that most of the peptides tested induced IFN-γ pro-
duction from CD4+ and/or CD8+ T cells confirming the results
obtained with in silico analysis (Figures 2B,D).
Furthermore, specific antibodies of IgG class, as well as of IgG1
and IgG2a isotypes, were detected in the serum of mice immu-
nized with each synthetic peptide emulsified in CFA/IFA, 15 days
post third immunization, in order to evaluate peptide effect on
humoral response. According to the results, all the synthetic multi-
epitope peptides were able to induce the secretion of specific IgG
antibodies (Figures 3A,B). Of these, CPA_p2, CPA_p3, LeIF_p3,
and LeIF_p6 induced the highest secretion, followed by KMP-
11_p1, LeIF_p1, H1_p1, and H1_p3. Analysis of isotype pattern
showed that CPA_p2 strongly induced the production of both
IgG2a and IgG1 isotypes, followed by CPA_p3, while LeIF_p3
induced the production of IgG2a> IgG1 (Figure 3C). In con-
trast,LeIF_p6 strongly induced the production of IgG1 isotype and
weakly the production of IgG2a isotype. The other four peptides,
KMP-11_p1, LeIF_p1, H1_p1, and H1_p3, had insignificant effect
on the production of these two IgG isotypes.
Next, we employed a structure-based method for further analy-
sis of the tertiary structure of the most promising synthetic pep-
tides (CPA_p2, CPA_p3, H1_p3, LeIF_p3) that bound to HLA-A2
or HLA-DRB1 molecule, since HLA-restricted epitopes were also
nested in peptide sequences according to algorithms prediction
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FIGURE 2 | Multi-epitope peptide-specific cytokine production by CD4+
and CD8+ T cells. Spleen cells from BALB/c mice (n=5/group) immunized
either with individual peptide emulsified in CFA/IFA or PBS alone, were
re-stimulated in vitro with the respective peptide (10µg/ml) for 48 h, and
analyzed for CD4+ and CD8+ T cells producing IL-4 and IFN-γ.
(A–C) Representative FACS plots of intracellular staining used to define IL-4-
and IFN-γ-expressing CD4+ and CD8+ T cells in spleens derived from
immunized mice. Values represent the percentages of (A) IL-4+ cells among
CD4+ T cells and (B,C) IFN-γ+ cells among CD4+ and CD8+ T cell
populations. (D) Quantification of IL-4 and IFN-γ producing T cells in
immunized mice. All data were normalized to CFA/IFA control group. Each
bar represents the mean proportion of IL-4- and IFN-γ-producing CD4+ and
CD8+ T cells induced by the respective peptide.
(Table 4). Selection of HLA-A2 and HLA-DRB1 molecules was
based on published data demonstrating high frequency of these
supertypes in human population (54, 55). The ClusPro program
was run to predict docked conformations presenting good surface
complementarity with the two MHC molecules mentioned above.
The most probable 3D models according to algorithm analysis
indicating peptides located onto the peptide-binding cleft of the
MHC molecules with good surface complementarity are presented
in Figure 4.
DISCUSSION
In the perspective of second generation vaccines, a variety of dif-
ferent parasite molecules, such as secretory or transmembrane
proteins, including enzymes and receptors, has been tested to
date as candidate antigens for anti-Leishmania vaccine devel-
opment (56). Among them, CPA, Histone H1, KMP-11, and
LeIF were found to be highly immunogenic as described in
murine experimental models, cured VL patients and L. infan-
tum infected dogs and have been considered as potential vac-
cine candidates (39–41, 44, 45, 57). The induction of an effec-
tive T cell response against vaccine antigens requires antigen
processing and peptide presentation by antigen-presenting cells
(APCs), and it is well-established that T cells recognize the pep-
tide sequence in association to appropriate MHC molecules. The
discovery of MHC-binding motifs in proteins has led to the
development of several algorithms predicting MHC class I- and
II-restricted epitopes for presentation to CD8+ or CD4+ T cells,
respectively, accelerating research related to peptide-based vaccine
approach (15).
In the present study, we investigated the use of three algo-
rithms, SYFPEITHI, BIMAS, and NetMHCII to predict sequences
in CPA, Histone H1, KMP-11, and LeIF able to bind to MHC
class I and II molecules of the H2d haplotype. Furthermore,
combining this approach with experimental validation in MHC
compatible BALB/c mice, we determined epitopes in each protein
and designed multi-epitope peptides capable to induce peptide-
specific T cell proliferation and cytokine production by CD4+
and/or CD8+ T cells.
The analysis of protein sequences yielded a significant number
of possible epitopes from all four proteins, but only few of them
were predicted by all algorithms used with binding efficiency to
more than one supertypes or alleles. Interestingly, comparison of
predicted peptides for each MHC class I and II alleles showed a
low overlapping level between the results obtained from different
algorithms used in the study, indicating the significant differences
existing in the database source of building matrix motifs and dif-
ferent forms of scoring function of each algorithm. Also, it was
observed an antigenic region clustering. Based on these findings
and to the fact that prediction of MHC class I-restricted epi-
topes is considered more reliable (>85%) than that of MHC class
II-restricted epitopes, we designed eight multi-epitope peptides
for all proteins, based predominantly on highly scored MHC
class I-restricted epitopes. Adjacent or overlapping MHC class II-
restricted epitopes scored high were also nested in each synthetic
peptide. These multi-epitope peptides contained epitopes recog-
nized also by HLA class I and II molecules as defined by in silico
analysis. Until now, very few vaccine antigens against different
pathogens such as viruses, bacteria, and parasites, contain promis-
cuous T cell epitopes that have the ability to induce T cell-mediated
protective immune responses both in mice and human by binding
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FIGURE 3 | Multi-epitope peptide-specific antibody production. BALB/c
mice (n=9/group) immunized either with individual peptide emulsified in
CFA/IFA or PBS alone, were bled 15 days post third immunization and sera
were separated. (A,B) total IgG Abs, and (C) IgG1 and IgG2a Abs against each
peptide were assessed by ELISA. The results are expressed as OD450 ±SD.
Significant differences between groups of mice immunized with each
synthetic peptide emulsified in CFA/IFA and the group of mice immunized
with CFA/IFA alone are indicated by * (P<0.05).
to several alleles of a supertype or between different supertypes
(58, 59). Thus, these promiscuous epitope-driven vaccines could
have the capacity of increasing the frequency of responders in
genetically variable species, such as human populations (60).
The success of many vaccines is dependent on IFNγ-secreting
CD4+ T cells recruitment for long term protection. This accounts
for better immunologic memory leading to sustained immunity
after healing of live infections (61, 62). CD4+ T cells are activated
in terms of recognition of peptides-MHC class II complexes in
the surface of APCs after protein processing in cells’ endocytic
compartment. Activation of IFN-γ-producing CD4+ T cells plays
a pivotal role in protective immune responses against leishmani-
asis. Specifically, IFN-γ mediates macrophage activation against
both the promastigote and amastigote forms in H2O2-dependent
manner (63, 64) and nitric oxide production for parasite killing
(65). According to our results, CPA_p2, CPA_p3, LeIF_p3, and
LeIF_p6 induced peptide-specific IFN-γ production from CD4+
T cells in immunized mice indicating the processing and recog-
nition of MHC class II-specific epitopes by CD4+ T cells. CPA
and LeIF are considered significant candidate proteins for vac-
cine design against leishmaniasis. In the case of CPA, it has been
shown that administration of plasmid encoding CPA induced spe-
cific TH1 immune responses resulting to partial protection against
L. major in the experimental model of CL. However, protection
was significantly enhanced when co-administered with CPB or as
CPA/B hybrid protein (25–27), indicating the need of CPA co-
administration with another protein or adjuvant. On the other
hand, LeIF was originally described as a TH1-type natural adju-
vant and as an antigen inducing an IL-12 mediated TH1 response
in the PBMCs of leishmaniasis patients (39). LeIF is also capable
of inducing the secretion of cytokines IL-12, IL-10, and TNF-α by
APCs from healthy individuals (52, 66, 67). Furthermore, recom-
binant trifusion vaccines (leish111; leish110f) were developed by
incorporating the amino-terminal region of LeIF antigen. These
vaccines were shown to be efficient in experimental or clinical
trials for vaccination or immunotherapy (68).
Existing data suggest that secretory and surface exposed pro-
teins strongly induce specific CD8+ T cell responses (69, 70). A
previous study applying in silico analysis revealed that a high num-
ber of peptides derived from L. major secretome could bind to H2
BALB/c molecules (71). Several studies have shown the great role
played by CD8+ T cells in protective immune responses against
parasite in the susceptible BALB/c strain (72–74). Specifically,
CD8+ T cells either contributed in the destruction of Leishma-
nia-infected cells by activating macrophages to oxidative burst via
cytokines produced upon antigen stimulation (75, 76), or regu-
lating CD4+ T cell-mediated immune responses (77, 78). In our
study, both synthetic multi-epitope peptides of CPA, CPA_p2, and
CPA_p3, except from CD4+IFN-γ+ T cells activation, induced sig-
nificant IFN-γ production by CD8+ T cells. CPA_p2 and CPA_p3
belong to the secreted region of CPA as SignalP analysis showed
(30, 31). Interestingly, another study applying in silico analysis in
CPA sequence with MULTIPRED algorithm indicated the exis-
tence of four highly immunogenic regions recognized by the
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FIGURE 4 | Synthetic multi-epitope peptides docking. Ribbon diagram of
3D structural analysis of interactions between (A) HLA-A2 molecule
(PDB-code: 1HHG) and the synthetic peptides CPA_p2, CPA_p3, H1_p3, and
LeIF_p3, and (B) HLA-DRB1 molecule (PDB-code: 2SEB) and the synthetic
peptides CPA_p2 and LeIF_p3. Candidate peptides were predicted to locate
onto the peptide-binding cleft of the HLA molecules by using ClusPro
program. The side and top view are shown, the α strands were shown in
green, the β strands in blue, and the multi-epitope peptides in magenta.
HLA-A2 supertype (79), which harbored parts from our CPA
multi-epitope peptides.
As for KMP-11, KMP-11_p1 belonged to the amino-terminal
region of the protein and in contrast to previous observations this
synthetic peptide was proved to be poorly immunogenic, indi-
cated by the absence of peptide-specific proliferative response and
cytokine secretion in immunized mice. Previous studies concern-
ing the identification of T cell epitopes using infected macrophages
or DCs as APCs, revealed the existence of potential HLA class I-
and II-restricted T cell epitopes in the amino-terminal region,
characterizing a dominant cluster between position 1 and 33 of
KMP-11 sequence that could trigger specific cellular immune
responses in L. donovani- or L. panamensis-infected volunteers
(80, 81). Furthermore, hybrid-cell, DNA-based or heterologous
KMP-11-DNA/rVV based vaccination exhibited immunoprotec-
tive capacity in susceptible VL murine models. Protection was
accompanied with generation of antigen specific CD4+ and CD8+
T cells that produced effector cytokines such as IFN-γ, IL-2, and
TNF-α (36–38, 82, 83). Also in a previous work, we demonstrated
that vaccination with ex vivo pulsed bone marrow-derived den-
dritic cells with KMP-1112–31aa peptide and CpG as adjuvant
induced strong Th1 and Th17 protective immune responses in
murine model of VL (50). However, in the present study it is note-
worthy that secretion of IL-10 was also abrogated. These results
together suggest that KMP-11_p1 may be consisted from nat-
ural epitopes contributing in parasite host immunomodulation,
allowing parasite dissemination rather than stimulate protective
immune responses.
However, not only external or secreted Leishmania antigens
are able to be presented in the context of MHC class I mole-
cules but also intracellular proteins (84, 85). As such, in our study
H1_p1 and H1_p3 induced a T cell response characterized mainly
by CD8+ T cell priming and production of IFN-γ in immunized
mice. Although, this way of cell activation in leishmaniasis remains
controversial and it is not clear how non-secretory parasite anti-
gens such as histone H1 can be presented endogenously in the
context of MHC class I molecules, a number of studies supports
the induction of specific CD8+ T cell responses against struc-
tural parasite proteins in animal models and VL patients (82, 84,
86, 87). Previous results from our group supported that ex vivo
pulsed bone marrow-derived dendritic cells with the Leishma-
nia histone H1 elicited significant protection in the experimental
model of VL, with a pronounced enhancement of parasite-specific
IFNγ-producing CD8+ T cells (88). The protective effect of Leish-
mania histone H1 against L. major or L. infantum infections
was also shown in different experimental animal models (34, 35)
suggesting that it is also a promising vaccine candidate against
leishmaniasis. In contrast, none of the LeIF peptides tested could
evoke specific CD8+ T cell responses. This finding was in agree-
ment with the study of Rafati et al. showing that PBMCs from
patients recovered from L. major failed to elicit HLA-A2-restricted
CD8+ T cell responses against three synthetic nonamer peptides
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of LeIF, suggesting that these peptides are not able to induce a
CD8+ T cell-induced protective immunity (86).
The relative low concentrations of IL-10 detected in the super-
natants of immune lymphocytes compared to IFN-γ after peptide
re-stimulation were consistent with the suggestion of a dynamic
reciprocal relationship between these two cytokines. IL-10 pri-
marily down-modulates innate as well as acquired immunity
leading to parasite establishment or disease progression. In exper-
imental model of VL, IL-10 prevents DCs migration in spleen
to activate T cells (89, 90) and suppresses both TH1 and TH2
cells (91). Also, the CD4+IL-4+ T lymphocytes detected in the
presence of all peptides may be attributed to BALB/c intrin-
sic feature to induce the production of type-2 cytokines, such
as IL-4 (53), since there was not any significant difference of
IL-4 levels between peptide-immunized mice and control mice
receiving the adjuvant alone. Furthermore, IFA adjuvant has a
propensity to induce preferentially TH2 cytokines (92, 93). Similar
study for the evaluation of immunoreactivity of in silico pre-
dicted TH1 epitopes of Schistosoma japonicum showed that high
levels of IL-4 were attributed to Freund’s adjuvant and BALB/c
strain used (94). Therefore, in terms of proportion of intracellu-
lar cytokine production of recall CD8+ and CD4+ T cells, it is
concluded that CPA_p3, H1_p1, H1_p3, CPA_p2, LeIF_p3, and
LeIF_p6 synthetic multi-epitope peptides are likely to include
potential epitopes for the induction of protective cytotoxic (CTL)
and TH1-type immune responses. Taken into account that the
sequences of these synthetic peptides are highly conserved and
bind in a promiscuous manner to murine or human MHC mole-
cules according to in silico analysis and structure-based techniques,
make them candidate vaccines against leishmaniasis. Based on
these results, it would be worthwhile conducting future investi-
gations for the verification of peptides’ possible ability to induce
protection in common or humanized mouse models of leishmani-
asis. The incorporation of alternative and/or additional epitopes,
the use of modern adjuvants and new antigen delivery systems
should be combined. Conclusively, these findings give comple-
mentary data on epitope mapping for Leishmania proteins and
demonstrate that combination of immunoinformatic approaches
with experimental validation enables peptide identification with
greater accuracy contributing to rational epitope-based vaccine
development.
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